## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($59.62)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 1)

**1. Bio-Techne Corp $TECH Shares Bought by JPMorgan Chase & Co.**
- Source: MarketBeat | 20251201T102333 | Neutral | Relevance: 100%
- JPMorgan Chase & Co. significantly increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 52.9% in Q2, acquiring 470,339 additional shares to own a total of 1,358,823 shares valued at approximately $69.9 million. This move comes as Bio-Techne reported Q2 EPS of $0.42, meeting estimates, but revenue of $286.56 million fell below consensus and was down 1% year-over-year. The company has a "Moderate Buy" consensus analyst rating with an average target price of $70.92, despite a high P/E ratio of 139.88.

**2. Edgestream Partners L.P. Has $11.81 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T105226 | Bullish | Relevance: 100%
- Edgestream Partners L.P. increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 15.9% in Q2, now holding 229,625 shares valued at $11.81 million. Institutional investors own approximately 98.95% of the company, and analysts have a "Moderate Buy" rating with a consensus price target of $70.92. Bio-Techne reported $0.42 EPS in line with estimates and declared a quarterly dividend of $0.08 per share.

**3. Capital Fund Management S.A. Invests $4.89 Million in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T100713 | Somewhat-Bullish | Relevance: 100%
- Capital Fund Management S.A. recently acquired a new stake of 95,046 shares in Bio-Techne Corp (NASDAQ:TECH) valued at approximately $4.89 million during the second quarter. This investment makes Capital Fund Management S.A. a significant institutional holder, owning about 0.06% of Bio-Techne. The article also details other institutional investor activities, analyst ratings, and Bio-Techne's recent financial performance and dividend announcement.

**4. Mackenzie Financial Corp Raises Stock Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T121908 | Somewhat-Bullish | Relevance: 100%
- Mackenzie Financial Corp increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 2.9% to 2,619,101 shares, valued at approximately $134.8 million. This comes amidst a "Moderate Buy" average analyst rating and updated price targets from several firms. Bio-Techne reported Q3 EPS of $0.42, meeting estimates, and revenue of $286.6 million, slightly below expectations.

**5. Rhumbline Advisers Has $15.16 Million Stock Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T103334 | Neutral | Relevance: 100%
- Rhumbline Advisers reduced its stake in Bio-Techne Corp by 1.9% in Q2, ending the quarter with 294,621 shares valued at $15.16 million. Bio-Techne reported Q2 EPS of $0.42 and revenue of $286.56 million, slightly below estimates. The company has a "Moderate Buy" rating from analysts with a consensus price target near $70.92.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |
| 2025-11-06 | UBS | $70 | $65 | +8% |
| 2025-11-06 | Wells Fargo | $70 | $59 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 29.4x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 29.4 |
| Current P/E | 32.3 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.3% to 2.9% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.1pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.9% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.94% (CS: 77) | Neutral |
| RSI_14 | 57.9 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.150x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $63.82
- **Stop Loss:** $59.62 (6.6% risk)
- **Target:** $72.22 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 226
- **Position Value:** $14,423.32
- **Portfolio %:** 14.42%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*